{
    "clinical_study": {
        "@rank": "104066", 
        "acronym": "MAINRITSAN 2", 
        "arm_group": [
            {
                "arm_group_label": "Rituximab infusion according biological parameters", 
                "arm_group_type": "Experimental", 
                "description": "Rituximab infusion based on ANCA and CD19 lymphocytes"
            }, 
            {
                "arm_group_label": "Systematic rituximab infusion", 
                "arm_group_type": "Active Comparator", 
                "description": "Semestrial rituximab infusion until 18 months"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to assess the efficacy of a rituximab regimen based on rate of ANCA\n      and CD19 lymphocytes for maintenance treatment in systemic ANCA-associated vasculitis:\n      prospective, multicenter, controlled, randomized comparative study of two rituximab\n      regimens: one based on ANCA and CD19 lymphocytes versus systematic infusions."
        }, 
        "brief_title": "Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis", 
        "completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Granulomatosis With Polyangiitis", 
            "Microscopic Polyangiitis", 
            "Renal Limited Forms"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Vasculitis", 
                "Wegener Granulomatosis", 
                "Systemic Vasculitis", 
                "Microscopic Polyangiitis", 
                "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Randomized, controlled, national, multicenter, prospective study to compare systematic\n      rituximab infusions (conventional therapy) to rituximab infusion based on rate of ANCA and\n      CD19 lymphocytes in patients with systemic ANCA-associated vasculitis, in remission\n      (achieved with an induction treatment combining corticosteroids and an immunosuppressant\n      after the first flare of the disease (new diagnosis) or after a relapse. Patients will be\n      stratified by first flare (66% of the patients) or relapse (33% of the patients). Patients\n      complying with the inclusion criteria may be included when they are in remission from their\n      vasculitis. Patients will be included at the time of remission and then randomized. They\n      will receive maintenance treatment by 1)2 rituximab infusions mg at D1, D15 then every 6\n      months until month 18 (i.e. a total of 5 infusions), at the dose of 500 mg. 2) 1 rituximab\n      infusion at the dose of 500 mg at D0 then ANCA status and CD19+ lymphocyte count will be\n      monitored every 3 months, and patients will receive new 500 mg rituximab infusions either if\n      CD19 are > to 0/mm3, or if ANCA are positive again or if ANCA titer significantly raises.\n      After the 18 month length of maintenance phase, i.e. after stopping immunosuppressive\n      maintenance therapy, patients will be followed for an additional 10 month period. Patients\n      with granulomatosis with polyangiitis will be prescribed cotrimoxazole 160/800 tid (for 2\n      additional years)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Granulomatosis with Polyangiitis Or microscopic polyangiitis complying Or\n             kidney-limited disease With or without detectable ANCA (anti-neutrophil cytoplasmic\n             antibodies) at the time of diagnosis or relapse, and at remission.\n\n          -  Who have achieved remission using a treatment combining corticosteroids and an\n             immunosuppressive agent, including corticosteroids, cyclophosphamide IV or oral (the\n             use of another immunosuppressant is allowed, according to the current French\n             guidelines, as well as plasma exchanges and/or IV immunoglobulins, or rituximab).\n\n          -  Interval of 1 month between the end of the immunosuppressant treatment and the\n             randomization time if cyclophosphamide or methotrexate were used, interval between 4\n             and 6 months if rituximab was used\n\n          -  Age > 18 years without age limit higher when the diagnosis is confirmed.\n\n          -  Informed and having signed the consent form to take part in the study.\n\n        Exclusion Criteria:\n\n          -  Other systemic vasculitis\n\n          -  Secondary vasculitis (following neoplastic disease or an infection in particular)\n\n          -  Induction treatment with a regimen not corresponding to that recommended in France.\n\n          -  Patient who has not achieved remission.\n\n          -  Incapacity or refusal to understand or sign the informed consent form.\n\n          -  Incapacity or refusal to adhere to treatment or perform the follow-up examinations\n             required by the study. Non-compliance\n\n          -  Allergy, documented hypersensitivity or contraindication to the study medication\n             (cyclophosphamide, corticosteroids, azathioprine, rituximab)\n\n          -  History of severe allergic or anaphylactic reactions to humanized or murine\n             monoclonal antibodies.\n\n          -  Pregnancy, breastfeeding. Women of childbearing age must use a reliable method of\n             contraception throughout the duration of immunosuppressive treatment up to 1 year\n             after the last infusion of rituximab\n\n          -  Infection by HIV, HCV or HBV\n\n          -  Progressive, uncontrolled infection requiring a prolonged treatment (tuberculosis,\n             HIV infection, etc.).\n\n          -  Severe infection declared during the 3 months before randomization (CMV, HBV, HHV8,\n             HCV, HIV, tuberculosis).\n\n          -  Progressive cancer or malignant blood disease diagnosed during the 5 years before the\n             diagnosis of vasculitis. Patients suffering from non-metastatic prostate cancer or\n             those cured of a cancer or a malignant blood disorder for more than 5 years and not\n             taking any antineoplastic agents for more than 5 years may be included.\n\n          -  Participation in another clinical research protocol during the 4 weeks before\n             inclusion.\n\n          -  Any medical or psychiatric disorder which, in the investigator's opinion, may prevent\n             the administration of treatment and patient follow-up according to the protocol,\n             and/or which may expose the patient to a too greater risk of an adverse effect.\n\n          -  No social security\n\n          -  Churg and Strauss syndrome\n\n          -  Viral, bacterial or fungic or mycobacterial infection uncontrolled in the 4 weeks\n             before the inclusion\n\n          -  History of deep tissue infection (fasciitis, osteomyelitis, septic arthritis)in the\n             first year before the inclusion\n\n          -  History of chronic and severe or recurrent infection or history of preexisting\n             disease predisposing to severe infection\n\n          -  Severe immunodepression\n\n          -  Administration of live vaccine in the four weeks before inclusion\n\n          -  Severe chronic obstructive pulmonary diseases (VEMS < 50 % or dyspnea grade III)\n\n          -  Chronic heart failure stade III and IV (NYHA)\n\n          -  History of recent acute coronary syndrome, unrelated to vasculitis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "166", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01731561", 
            "org_study_id": "P110146", 
            "secondary_id": "2012-001963-66"
        }, 
        "intervention": [
            {
                "arm_group_label": "Rituximab infusion according biological parameters", 
                "description": "Rituximab infusion will be performed at D1 then ANCA status and CD19+ lymphocyte count will be monitored every 3 months, and patients will receive new 500 mg rituximab infusions either if CD19 are > to 0/mm3, or if ANCA are positive again or if ANCA titer significantly raises. All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.", 
                "intervention_name": "Rituximab (Arm B)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Systematic rituximab infusion", 
                "description": "Rituximab infusion will be performed at D1, D15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.", 
                "intervention_name": "Rituximab (Arm A)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Granulomatosis with Polyangiitis", 
            "Microscopic polyangiitis", 
            "Renal limited forms", 
            "ANCA-associated vasculitis", 
            "Rituximab"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "link": {
            "description": "Website of the French Vasculitis Study Group", 
            "url": "http://www.vascularites.org"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France", 
                    "zip": "75014"
                }, 
                "name": "Cochin Hospital"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II", 
        "overall_official": [
            {
                "affiliation": "Cochin Hospital, Paris, France", 
                "last_name": "Loic Guillevin, MD, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Institut mutualiste, Paris, France", 
                "last_name": "Pierre Charles, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of relapses (BVAS>0) majors and minors in each group at the end of the maintenance treatment (18 months treatment + 16 months follow-up)", 
            "measure": "Number of relapses", 
            "safety_issue": "No", 
            "time_frame": "at 28 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01731561"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of patients with ANCA in each group", 
                "measure": "Number of patients with ANCA (Anti-Neutrophil Cytoplasmatic Antibodies)", 
                "safety_issue": "No", 
                "time_frame": "at 28 months"
            }, 
            {
                "description": "To assess the number of adverse events and their severity in each group", 
                "measure": "Number of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "at 28 months"
            }, 
            {
                "description": "To assess mortality rate in each group", 
                "measure": "Mortality rate", 
                "safety_issue": "No", 
                "time_frame": "at 28 months"
            }, 
            {
                "description": "number of minor relapse in each group", 
                "measure": "Number of minor relapse", 
                "safety_issue": "No", 
                "time_frame": "at 28 months"
            }, 
            {
                "description": "Cumulated dose of corticosteroid treatment in each group at 34 months", 
                "measure": "Cumulated dose of corticosteroid treatment", 
                "safety_issue": "No", 
                "time_frame": "at 28 months"
            }, 
            {
                "description": "Number and severity of damages in each group", 
                "measure": "Number and severity of damages", 
                "safety_issue": "Yes", 
                "time_frame": "at 28 months"
            }, 
            {
                "description": "Evolution of ANCA in each group and the link of the clinical events", 
                "measure": "Evolution of ANCA and the link of the clinical events", 
                "safety_issue": "No", 
                "time_frame": "at 28 months"
            }, 
            {
                "description": "Distribution of events by severity and it will be assigned to the drug and its mode of administration and/or the severity of the disease (in each group).", 
                "measure": "Distribution of events by severity", 
                "safety_issue": "No", 
                "time_frame": "at 28 months"
            }, 
            {
                "description": "The length of corticosteroid treatment in each group at 34 months", 
                "measure": "Length of corticosteroid treatment", 
                "safety_issue": "No", 
                "time_frame": "at 28 months"
            }, 
            {
                "description": "The rate of B-Lymphocytes CD-19 and the link of the clinical events", 
                "measure": "Rate of B-Lymphocytes CD-19 and the link of the clinical events", 
                "safety_issue": "No", 
                "time_frame": "at 28 months"
            }
        ], 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}